Activities of anti-duck hepatitis B virus of three novel nucleoside analogues and their effects on histomorphology of duck liver
Di WU,Jun-qi NIU,Wan-guo BAO,bo-hua ZHONG,Xin-yu WU,Yan-hua DING,Xiang-wei FENG
DOI: https://doi.org/10.13481/j.1671-587x.2011.06.029
2011-01-01
Abstract:Objective: To study the activities of anti-duck hepatitis B virus (anti-DHBV) of three novel nucleoside analogues and their effects on histomorphology of duck liver, and to explore novel potential anti-HBV agents. Methods: The anti-DHBV activities were analyzed by fluorescent quantitative PCR in experimental groups with various doses of 030703, 030605, 030705 (2, 10 and 50 mg·kg -1) and adefovir dipioxil control group (10 mg·kg -1). Compounds were taken by oral administration per day and last 30 d. The serum specimens were obtained at the time of before adminstration, 15 d and 30 d after administration and 2 weeks after withdraw. The serum DHBV DNA was detected with fluorescence quantitative PCR. At the same time, DHBV DNA positive and negative groups were set up. The duck liver specimens were obtained after experiment. The histomorphological changes of duck liver caused by three tested compounds were observed under optic microscope. Results: After administration with compound 030703, there were 3 ducks (60%) in high dose group, 2 ducks (40%) in middle dose group, 1 duck (20%) in low dose group, in which the DHBV DNA contents were decreased to 1/3 of primary contents; compared with adefovir dipioxil control group, the inhibitory effects in high dose group had significant difference (P<0.01), whereas the inhibitory effects in middle and low dose groups had no significant difference (P>0.05). After administration with compound 030605, there were 4 ducks (80%) in high dose group, 3 ducks (60%) in middle dose group, 1 duck (20%) in low dose group, in which the DHBV DNA contents were decreased to 1/3 of primary contents; compared with adefovir dipioxil control groups, the inhibitory effects in high dose group and middle group had significant difference (P<0.01), whereas the inhibitory effect in low dose group had no significant difference (P>0.05). After administration with compound 030705, there were 3 ducks (60%) in high dose group, 2 ducks (40%) in middle dose group, 0 duck (0%) in low dose group, in which the DHBV DNA contents were decreased to 1/3 of primary contents; compared with adefovir dipioxil control groups, the inhibitory effects in high dose group had significant difference (P<0.01), whereas the inhibitory effects in middle and low groups had no significant difference (P>0.05). Compared with adefovir dipioxil control group, the effects of all three test compounds (high, middle and low dose groups) on duck liver inflammation were similar to that in adefovir dipioxil control group. Conclusion: Three novel test compounds 030703, 030605 and 030705 have obvious anti-DHBV activities and might improve duck liver inflammation to some extent. It has been suggested that all of these novel compounds be potential anti-HBV agents.